Merus N.V. (MRUS)
43.05
1.14 (2.72%)
At close: Apr 17, 2025, 3:59 PM
43.05
0.00%
After-hours: Apr 17, 2025, 04:05 PM EDT
2.72% (1D)
| Bid | 40 |
| Market Cap | 2.97B |
| Revenue (ttm) | 36.13M |
| Net Income (ttm) | -215.33M |
| EPS (ttm) | -3.35 |
| PE Ratio (ttm) | -12.85 |
| Forward PE | -9.8 |
| Analyst | Buy |
| Ask | 55.95 |
| Volume | 316,799 |
| Avg. Volume (20D) | 686,887 |
| Open | 42.12 |
| Previous Close | 41.91 |
| Day's Range | 42.33 - 43.21 |
| 52-Week Range | 33.19 - 61.61 |
| Beta | 1.03 |
About MRUS
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also de...
Industry Biotechnology
Sector Healthcare
IPO Date May 19, 2016
Employees 260
Stock Exchange NASDAQ
Ticker Symbol MRUS
Website https://www.merus.nl
Analyst Forecast
According to 12 analyst ratings, the average rating for MRUS stock is "Buy." The 12-month stock price forecast is $84.5, which is an increase of 96.26% from the latest price.
Stock ForecastsNext Earnings Release
Merus N.V. is scheduled to release its earnings on May 7, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
+5.15%
Merus shares are trading higher after the company ...
Unlock content with
Pro Subscription
3 months ago
-7.75%
Merus shares are trading lower. The company announced a research collaboration and license agreement with Biohaven to co-develop three novel bispecific antibody drug conjugates.
